new technologies competing with glp-1 medications 2025 Novo cuts prices 70%, but semaglutide revenue could grow in 2026 Designing GLP-1 delivery: structural perspectives

GLP-1RA therapy inhibits glucagon secretion, at least transiently delays gastric emptying, and reduces appetite and food intake [60,61]

Honestly, anything that feels like comfort food without being greasy

Intake flows and questionnaires adapted by persona Our intake flows go way beyond height, weight, and meds. We collect the inputs that actually predict outcomes and adherencenutrition patterns, readiness signals, barriers, motivation, support environment, and the real reason someone wants to lose weight

Genetic overlap between MDD and T2DM was also explored through Mendelian randomization studies, revealing insights into the causal relationships

Ashcroft, F

Since metformin has been shown to decrease the risk of pancreatic cancer, at the least we would suggest that GLP-1based medications should be reserved for patients taking metformin